Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation

被引:37
|
作者
Skidmore, F. M. [1 ]
Drago, V. [2 ]
Foster, P. [2 ]
Schmalfuss, I. M. [3 ]
Heilman, K. M. [2 ]
Streiff, R. R. [1 ]
机构
[1] Univ Florida, Sch Med, N Florida S Georgia VA Med Ctr, McKnight Brain Inst,Dept Med,Div Hematol, Gainesville, FL 32610 USA
[2] Univ Florida, Sch Med, Dept Neurol, Gainesville, FL USA
[3] N Florida S Georgia VA Med Ctr, Serv Radiol, Gainesville, FL USA
来源
关键词
D O I
10.1136/jnnp.2007.120568
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Hereditary aceruloplasminaemia is a disorder of iron metabolism that is characterised by iron accumulation in the brain and other visceral organs. In previously reported cases, individuals with the disorder were noted to have evidence of iron accumulation in the brain. Oral chelating agents have not been used in neurological diseases of iron metabolism. Methods: A 54-year-old woman who presented with ataxia, lower extremity spasticity and chorea was evaluated for evidence of the source of neurological dysfunction. Results: Blood studies revealed no detectable ceruloplasmin. Marked iron overload was defined by a liver biopsy, which showed a variegated pattern consistent with a primary cause of iron overload. Review of MRI scans showed progressive brain atrophy without visible iron accumulation occurring over a 5-year period. The history suggested that neurodegeneration was coincident with aggressive oral iron replacement. Oral chelation improved many symptoms. Conclusions: Our findings in this patient suggest that disorders of iron transport such as aceruloplasminaemia can be a cause of neurological symptoms such as chorea and cognitive decline, as well as progressive neurodegeneration in the absence of visible iron on MRI scans. We found that oral iron chelation was effective at improving symptoms.
引用
收藏
页码:467 / 470
页数:4
相关论文
共 50 条
  • [21] New oral iron-chelating drugs for the treatment of transfusional iron overload and other diseases
    Kontoghiorghes, GJ
    DRUGS OF THE FUTURE, 2005, 30 (12) : 1241 - 1251
  • [22] SUCCESSFUL TREATMENT OF CHRONIC LEG ULCERS WITH ORAL IRON CHELATORS IN A PATIENT WITH SYSTEMIC IRON OVERLOAD
    Sindrilaru, M. -A.
    Schriever, L.
    Huber, M.
    Gethoeffer, K.
    Peters, T.
    Schneider, L. A.
    Scharffetter-Kochanek, K. U.
    WOUND REPAIR AND REGENERATION, 2015, 23 (04) : A28 - A28
  • [23] CHANGES IN TRANSFERRIN SATURATION AFTER TREATMENT WITH THE ORAL IRON CHELATOR DEFERIPRONE IN PATIENTS WITH IRON OVERLOAD
    ALREFAIE, FN
    DESILVA, CE
    WONKE, B
    HOFFBRAND, AV
    JOURNAL OF CLINICAL PATHOLOGY, 1995, 48 (02) : 110 - 114
  • [24] Cardiac iron overload in patients with beta thalassaemia major: continued improvement and normalization of myocardial T2*with up to 3 years deferasirox (Exjade) oral iron chelation treatment
    Pennell, D. J.
    EUROPEAN HEART JOURNAL, 2011, 32 : 986 - 986
  • [25] Progressive Brain Atrophy and Cortical Thinning in Schizophrenia after Commencing Clozapine Treatment
    Ahmed, Mohamed
    Cannon, Dara M.
    Scanlon, Cathy
    Holleran, Laurena
    Schmidt, Heike
    McFarland, John
    Langan, Camilla
    McCarthy, Peter
    Barker, Gareth J.
    Hallahan, Brian
    McDonald, Colm
    NEUROPSYCHOPHARMACOLOGY, 2015, 40 (10) : 2409 - 2417
  • [26] Progressive Brain Atrophy and Cortical Thinning in Schizophrenia after Commencing Clozapine Treatment
    Mohamed Ahmed
    Dara M Cannon
    Cathy Scanlon
    Laurena Holleran
    Heike Schmidt
    John McFarland
    Camilla Langan
    Peter McCarthy
    Gareth J Barker
    Brian Hallahan
    Colm McDonald
    Neuropsychopharmacology, 2015, 40 : 2409 - 2417
  • [28] Transfusion Related Iron Overload in Pediatric Oncology Patients Treated at a Tertiary Care Centre and Treatment With Chelation Therapy
    Sait, Sameer
    Zaghloul, Nibal
    Patel, Ashish
    Shah, Tishi
    Iacobas, Ionela
    Calderwood, Stanley
    PEDIATRIC BLOOD & CANCER, 2014, 61 (12) : 2319 - 2320
  • [29] Oral Iron Chelation Therapy Prevents Diastolic Dysfunction in Chronic Iron Overload: Two-Year Follow-Up in Patients With Aplastic Anemia
    Chung, Woo-Baek
    Youn, Ho-Joong
    Hong, Eun-Ju
    Choi, Youn-Seok
    Oh, Yong-Seog
    Chung, Wook-Sung
    Kim, Jae-Hyung
    Lee, Jong-Wook
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (10) : A158 - A158
  • [30] Effect of availability of oral iron chelation therapy (ICT) on initiation, duration, and dose adequacy in patients with myelodysplastic syndromes (MDS) and transfusional iron overload (TIO).
    Gore, Steven
    Davidoff, Amy J.
    Hendrick, Franklin
    Vu Duong
    Stuart, Bruce C.
    Baer, Maria R.
    Shenolikar, Rahul
    Zeidan, Amer
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)